PIRAMAL PHARMA Latest Share Price (PPLPHARMA)
TODAY IN ONE LINE
PPLPHARMA dropped 3.2% on light volume, lagging Nifty's -1.6% move, supported by recent strong earnings.
With a market cap of ₹26,121.05 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
PIRAMAL PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●FII SellingFII holding decreased by 17.66% QoQ
Latest PIRAMAL PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
PIRAMAL PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for PIRAMAL PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
PIRAMAL PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for PIRAMAL PHARMA — derived from the latest tape, not yesterday's close.
PIRAMAL PHARMA last traded at ₹196.43 with an intraday range of ₹196–₹203.5 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹196.43| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 216.29 | +19.86 | +10.11% |
| R3 | 208.79 | +12.36 | +6.29% |
| R2 | 206.14 | +9.71 | +4.94% |
| R1 | 201.29 | +4.86 | +2.47% |
| PIVOT | 198.64 | 2.21 | 1.13% |
| CURRENT | 196.43 | — | — |
| S1 | 193.79 | -2.64 | -1.35% |
| S2 | 191.14 | -5.29 | -2.69% |
| S3 | 186.29 | -10.14 | -5.16% |
| S4 | 178.79 | -17.64 | -8.98% |
PPLPHARMA is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹199.11–₹203.5
Trading Below opening range, showing Bearishness
PIRAMAL PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for PIRAMAL PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
PIRAMAL PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹26,121.05 Cr. and reported EPS of ₹-0.52.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 9,151 | 8,869 ▼ 3.1% |
| Sales Growth YoY %Derived | 11.99% | -3.08% |
| Other Income | 135 | 213 ▲ 58.2% |
| Total Income | 9,286 | 9,082 ▼ 2.2% |
| 3,232 | 3,239 ▲ 0.2% | |
| Gross ProfitDerived | 5,920 | 5,631 ▼ 4.9% |
| Gross Margin %Derived | 64.69% | 63.49% |
| 4,475 | 4,709 ▲ 5.2% | |
| EBITDA (Operating Profit)Derived | 1,445 | 922 ▼ 36.2% |
| OPM %Derived | 15.79% | 10.39% |
| 1,238 | 976 ▼ 21.2% | |
| Profit Before Tax (PBT) | 342 | -233 ▼ 168.3% |
| 324 | 150 ▼ 53.7% | |
| Effective Tax %Derived | 94.67% | -64.25% |
| Total Profit for Period | 91 | -326 ▼ 457.7% |
| Net Profit (Owner's PAT)Derived | 91 | -326 ▼ 457.7% |
| Net Profit Margin %Derived | 1.00% | -3.68% |
| PAT Growth YoY %Derived | 411.39% | -457.66% |
| Earnings Per Share (EPS ₹) | 0.69 | -2.45 ▼ 455.1% |
| Diluted Shares Outstanding (Cr) | 133 | 133 ▲ 0.3% |
| Share of Profit from Associates/JVs | 73 | 57 ▼ 21.6% |
| Other Comprehensive Income (Net of Tax) | 80 | 338 ▲ 323.9% |
| Total Expenses (incl. D&A & Interest) | 8,944 | 9,316 ▲ 4.2% |
| Material Cost % of RevenueDerived | 22.46% | 22.50% |
| Employee Cost % of RevenueDerived | 25.21% | 27.24% |
| Other Cost % of RevenueDerived | 23.68% | 25.85% |
| Interest Coverage (x)Derived | 1.49x | 0.27x |
| Period | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|
| Revenue from Operations | 7,082 | 8,171 ▲ 15.4% | 9,151 ▲ 12.0% | 8,869 ▼ 3.1% | |
| Sales Growth YoY %Derived | — | 15.39% | 11.99% | -3.08% | |
| Other Income | 225 | 175 ▼ 22.1% | 135 ▼ 23.1% | 213 ▲ 58.2% | |
| Total Income | 7,307 | 8,347 ▲ 14.2% | 9,286 ▲ 11.3% | 9,082 ▼ 2.2% | |
2,703 | 2,954 ▲ 9.3% | 3,232 ▲ 9.4% | 3,239 ▲ 0.2% | ||
| Gross ProfitDerived | 4,378 | 5,217 ▲ 19.2% | 5,920 ▲ 13.5% | 5,631 ▼ 4.9% | |
| Gross Margin %Derived | 61.83% | 63.85% | 64.69% | 63.49% | |
3,750 | 4,021 ▲ 7.2% | 4,475 ▲ 11.3% | 4,709 ▲ 5.2% | ||
| EBITDA (Operating Profit)Derived | 628 | 1,196 ▲ 90.4% | 1,445 ▲ 20.8% | 922 ▼ 36.2% | |
| OPM %Derived | 8.87% | 14.64% | 15.79% | 10.39% | |
1,014 | 1,126 ▲ 11.1% | 1,238 ▲ 9.9% | 976 ▼ 21.2% | ||
| Profit Before Tax (PBT) | -174 | 120 ▲ 168.7% | 342 ▲ 185.2% | -233 ▼ 168.3% | |
66 | 161 ▲ 143.5% | 324 ▲ 100.4% | 150 ▼ 53.7% | ||
| Effective Tax %Derived | -38.00% | 134.78% | 94.67% | -64.25% | |
| Total Profit for Period | -186 | 18 ▲ 109.6% | 91 ▲ 411.4% | -326 ▼ 457.7% | |
| Net Profit (Owner's PAT)Derived | -186 | 18 ▲ 109.6% | 91 ▲ 411.4% | -326 ▼ 457.7% | |
| Net Profit Margin %Derived | -2.63% | 0.22% | 1.00% | -3.68% | |
| PAT Growth YoY %Derived | — | 109.56% | 411.39% | -457.66% | |
| Earnings Per Share (EPS ₹) | -1.41 | 0.13 ▲ 109.2% | 0.69 ▲ 430.8% | -2.45 ▼ 455.1% | |
| Diluted Shares Outstanding (Cr) | 132 | 132 ▼ 0.0% | 133 ▲ 0.2% | 133 ▲ 0.3% | |
| Share of Profit from Associates/JVs | 54 | 59 ▲ 9.5% | 73 ▲ 22.6% | 57 ▼ 21.6% | |
| Other Comprehensive Income (Net of Tax) | 176 | 57 ▼ 67.7% | 80 ▲ 40.7% | 338 ▲ 323.9% | |
| Total Expenses (incl. D&A & Interest) | 7,481 | 8,227 ▲ 10.0% | 8,944 ▲ 8.7% | 9,316 ▲ 4.2% | |
| Material Cost % of RevenueDerived | 23.76% | 24.19% | 22.46% | 22.50% | |
| Employee Cost % of RevenueDerived | 26.78% | 24.84% | 25.21% | 27.24% | |
| Other Cost % of RevenueDerived | 26.18% | 24.37% | 23.68% | 25.85% | |
| Interest Coverage (x)Derived | -0.14x | 1.02x | 1.49x | 0.27x |
PIRAMAL PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at PIRAMAL PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
PIRAMAL PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for PIRAMAL PHARMA.
Our AI distills the core fundamental drivers supporting PIRAMAL PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
PIRAMAL PHARMA's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.17. Balance sheet risk re-prices growth multiples fast.
PIRAMAL PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — PIRAMAL PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
PIRAMAL PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for PIRAMAL PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
PIRAMAL PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for PIRAMAL PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in PIRAMAL PHARMA stood at 39.0% of traded volume, against a 20-day average of 42.1%.
PIRAMAL PHARMA announcements: results, concalls, ratings, M&A.
Filings PIRAMAL PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
PIRAMAL PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 176 documents below.
Updates
Piramal Pharma Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of the SEBI (Listing Obligations and…
News Verification
The Exchange has sought clarification from Piramal Pharma Limited with respect to recent news item captioned Ontario Contributes $1.7 Million…
Change in Management
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015…
Change in Management
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015…
News Verification
The Exchange has sought clarification from Piramal Pharma Limited with respect to recent news item captioned Ontario Contributes $1.7 Million…
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Investor Presentation
Investor Presentation
PIRAMAL PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue PIRAMAL PHARMA has declared, sequenced by announce and record date.
PIRAMAL PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About PIRAMAL PHARMA: business, sector, key facts.
What PIRAMAL PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
PIRAMAL PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: PPLPHARMA, BSE: 543635.
Piramal Pharma Limited (PPLPHARMA) is a multinational pharmaceutical company with a global reach, encompassing North America, Europe, Japan, India, and other international markets. Its core business revolves around the development, manufacturing, and distribution of a diverse portfolio of pharmaceutical products and services. This broad approach allows them to cater to a wide range of needs within the industry.
A significant portion of PPLPHARMA's operations involves contract development and manufacturing organization (CDMO) services. This segment offers a comprehensive suite of services across the entire drug lifecycle. This includes assistance with drug discovery, development, and the commercial manufacturing of both drug substances and finished products. This CDMO arm positions PPLPHARMA as a key partner for other pharmaceutical companies needing outsourced manufacturing and development capabilities.
Beyond CDMO services, PPLPHARMA maintains a robust internal portfolio of pharmaceutical products. A key area of focus is their complex hospital generics business. This division specializes in high-demand products like inhalation anesthetics, intrathecal therapies used in spasticity management, injectable pain and anesthesia medications, and other specialized generic and branded products. This segment targets the hospital and healthcare sector, providing essential medications.
In addition to its global and hospital-focused operations, PPLPHARMA also has a substantial presence in the Indian consumer healthcare market. This domestic segment offers a wide array of over-the-counter (OTC) products targeting various health needs. Their consumer healthcare portfolio includes analgesics (pain relievers), skincare products, vitamin and mineral supplements, children's wellness products, digestive aids, women's health products, and hygiene and protection items. This diversification within the Indian market allows them to tap into a broad consumer base.
In summary, PPLPHARMA's business model is built on a multifaceted approach. They function as both a CDMO providing services to other pharmaceutical companies and a direct producer and distributor of their own branded and generic pharmaceutical products across various segments, including the hospital market and the Indian consumer healthcare market. This strategic diversification minimizes reliance on any single sector and positions the company for sustained growth.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about PIRAMAL PHARMA (PPLPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of PIRAMAL PHARMA (PPLPHARMA)?
The current share price of PIRAMAL PHARMA (PPLPHARMA) is ₹196.43. Today, the stock has declined by ₹6.58 (3.24%), trading in a range of ₹196.00 to ₹203.50. The stock opened at ₹203.50 with a trading volume of 18,96,685 shares.
02Is PIRAMAL PHARMA stock a good investment for long-term?
PIRAMAL PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹26,121.05 Cr., P/E ratio of 0, ROE of -3.99%, and ROCE of 0.86%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of PIRAMAL PHARMA stock?
The 52-week high price of PIRAMAL PHARMA (PPLPHARMA) is ₹231.93, while the 52-week low is ₹132.30. Currently trading at ₹196.43, the stock is 48.47% above its 52-week low and 15.31% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy PIRAMAL PHARMA stock at the current price?
Whether to buy PIRAMAL PHARMA stock at ₹196.43 depends on multiple factors. The stock is currently trading with a P/E ratio of 0 and P/B ratio of 3.19. Today's performance shows a loss of 3.24%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of PIRAMAL PHARMA and when is the next dividend?
PIRAMAL PHARMA offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹196.43, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of PIRAMAL PHARMA?
PIRAMAL PHARMA's key financial metrics include: P/E Ratio: 0, P/B Ratio: 3.19, ROE: -3.99%, ROCE: 0.86%, Dividend Yield: 0%, EPS: ₹-0.52, Book Value: ₹61.31, and Debt-to-Equity: 0.67. The company's market cap stands at ₹26,121.05 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is PIRAMAL PHARMA stock performing today in the market?
PIRAMAL PHARMA stock opened at ₹203.50 and is currently trading at ₹196.43, showing a decline of ₹6.58 (3.24%). The intraday high is ₹203.50 and low is ₹196.00. The trading volume stands at 18,96,685 shares, indicating strong market participation today.
08What is the P/E ratio of PIRAMAL PHARMA and what does it indicate?
PIRAMAL PHARMA has a Price-to-Earnings (P/E) ratio of 0, which means investors are willing to pay 0.00 for every ₹1 of earnings. With an EPS of ₹-0.52, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about PIRAMAL PHARMA (PPLPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.